Research on health inequality and genetic disparity in cardiovascular diseases
Official title: EMPOWER-1: A Multi-site Clinical Cohort Study to Reduce Health Inequality: Identifying Ethnic Disparities in Treatment Failures for Medicines Prescribed to Treat Diseases That Cause Significant Mortality and Morbidity in the UK Population
Run by Future Genetics Limited · NCT03987633 · Data updated 2026-11-12
This study is trying to understand how health differences and genetics affect heart diseases in people from various ethnic backgrounds in the UK to help improve treatments for everyone.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 6 Years and up |
| Sex | All |
| Enrollment | 200000 (estimated) |
| Sponsor | Future Genetics Limited Academic / other |
| Locations | 1 site (Wolverhampton, West Midlands) |
| Status | Recruiting |
| Started | February 1, 2020 |
| Main results expected | February 1, 2028 |
| Study ends | February 1, 2030 |
| Registry record updated | March 10, 2025 |
| Trial ID | NCT03987633 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients diagnosed with atrial fibrillation, coronary heart disease, heart failure, hypertension, or other cardiovascular diseases, particularly from the specified ethnic groups.
✕Probably not a fit
Patients who are not registered with the NHS or lack the capacity to provide consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to address health inequality and genetic disparity in the UK by recruiting up to 200,000 patients from diverse ethnic backgrounds, specifically White, African-Caribbean, and South Asian populations. It will analyze biological samples, medical records, and questionnaires to identify treatment failures in various cardiovascular diseases. The study seeks to provide real-world evidence on disease prevalence and inform clinical practices to improve health outcomes for underrepresented populations. By pooling data from multiple NHS sites, the research will ensure a meaningful representation of different ethnicities.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and health outcomes for diverse patient populations suffering from cardiovascular diseases.
How similar studies have gone: While the focus on health inequality and genetic disparity is increasingly recognized, this specific approach of large-scale, multi-ethnic cohort analysis is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients or their relative/family member is diagnosed with the illness being investigated by this study. 2. All NHS patients that are associated with a participating study site, but do not fall under the first bullet point above, may participate with a view that they may potentially contribute to a case control population in the research study. 3. Subjects agree to: 1. Gift biological samples, i.e. saliva. Where practical, blood or other biological samples may be voluntarily provided by the patient. 2. Provide Consent for access to medical records. 3. Complete disease specific, quality of life, and study associated questionnaires. Exclusion Criteria: 1. Patient does not provide a valid consent for study participation. 2. Patient is not registered with the NHS for care. 3. Patient lacking capacity, who does not have an illness that is being specifically investigated by this clinical research study. 4. Person lacks capacity and where the personal consultee has not advised that the Person may enrol, in accordance with the Mental Health Act 2005.
Where it's running
-
Future Genetics, The Science Centre, Wolverhampton Science Park
Wolverhampton, West Midlands, United Kingdom Recruiting
Study contacts
- Study coordinator: Dr Mohammed Kamran
- Email: director@futuregenetics.co.uk
- Phone: 00441216673007
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Adapting and testing PEN-Plus in Zambian primary care
Aiming to see if the PEN-Plus package can be adapted and used in two Zambian hospitals to better manage chronic diseases like heart disease, diabetes, hypertension, and sickle cell in primary care.
-
Home-based cardiovascular health screening for people turning 50, 55, 60, 65, 70 or 75 in Uppsala
This trial tests whether giving people a home blood pressure monitor, a dried blood spot kit, and a questionnaire can find more cardiovascular risk factors than usual care.
-
Streamlined renal denervation with Spyral for uncontrolled high blood pressure
This trial will test whether a shorter, simpler renal denervation procedure using the Symplicity Spyral system can lower blood pressure in adults with uncontrolled hypertension.
-
Gemini multi-organ denervation for uncontrolled high blood pressure
The Gemini System is being tested to see if multi-organ denervation is safe and can lower blood pressure in adults with uncontrolled hypertension, with or without high cardiovascular risk.
-
Integrated care for older patients with atrial fibrillation
This study is testing a new team-based care approach for older patients with atrial fibrillation and other health issues to see if it helps them manage their condition better than regular care.
-
Lifestyle medicine program to help rural adults with multiple chronic conditions
This program will try supervised exercise and lifestyle coaching for rural adults aged 18–64 who have two or more chronic conditions to see if access to a wellness facility improves their health.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.